Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 2

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 2
---
 this distribution process to conserve natural resources and reduce the costs of printing and distributing our proxy materials. We encourage all stockholders to attend the Annual Meeting online. Whether or not you plan to attend the Annual Meeting online, we encourage you to read this Proxy Statement and submit your proxy or voting instructions as soon as possible by using the internet as described in the instructions included on your Notice, by calling the toll-free telephone number included in the Proxy Statement, or, if you received a paper copy of the proxy materials, by completing, signing, dating and returning your proxy card. Further information about how to register for the Annual Meeting, attend the Annual Meeting online, vote your shares and submit questions for consideration at the meeting is included in the accompanying Proxy Statement. A complete list of registered stockholders will be available to stockholders of record for examination at www.proxydocs.com/AGIO during the 10-dayperiod ending on the day before the Annual Meeting Thank you for your ongoing support and continued interest in Agios Pharmaceuticals, Inc. By Order of the Board of Directors, Brian Goff Chief Executive Officer Cambridge, Massachusetts April 25, 2025

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be Held on June18, 2025:This Proxy Statement and our 2024 Annual Report to Stockholders are available at www.proxydocs.com/AGIO. These documents are also available to any stockholder who wishes to receive a paper copy by calling (866) 648-8133, visiting www.investorelections.com/AGIOor emailing paper@investorelections.com.

#### TABLE OF CONTENTSPagePROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS1GENERAL INFORMATION ABOUT THE ANNUAL MEETING AND VOTING1STOCKHOLDERS SHARING THE SAME ADDRESS10SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT11DELINQUENT SECTION 16(a) REPORTS13PROPOSAL 1: ELECTION OF DIRECTORS14CORPORATE GOVERNANCE20EXECUTIVE OFFICERS38EXECUTIVE COMPENSATION40CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS80PROPOSAL 2: ADVISORY VOTE ON EXECUTIVE COMPENSATION82PROPOSAL 3: APPROVAL OF AN AMENDMENT TO THE AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN83PROPOSAL 4: RAT